Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,199,013 papers from all fields of science
Search
Sign In
Create Free Account
AXL Inhibitor BGB324
Known as:
BGB324
An orally available and selective inhibitor of the AXL receptor tyrosine kinase (UFO), with potential antineoplastic activity. Upon administration…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
NCIt Antineoplastic Agent Terminology
Receptor Tyrosine Kinase Inhibition
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
First-in class selective AXL inhibitor bemcentinib (BGB324) in combination with LDAC or decitabine exerts anti-leukaemic activity in AML patients unfit for intensive chemotherapy: Phase II open-label…
S. Loges
,
M. Heuser
,
+17 authors
B. Gjertsen
Journal of Clinical Oncology
2019
Corpus ID: 199045151
7043 Background: The RTK AXL represents a therapeutic target promoting AML cell proliferation and survival by pleiotropic…
Expand
Review
2018
Review
2018
The Role of the TAM Family of Receptor Tyrosine Kinases in Neural Development and Disorders
Jun Zhang
,
Xin Qi
2018
Corpus ID: 13710361
Tyrosine kinase receptor 3 (Tyro3), Axl, and Mer constitute the TAM family of receptor tyrosine kinases. These receptor tyrosine…
Expand
2018
2018
Combination of bemcentinib (BGB324): A first-in-class selective oral AXL inhibitor, with pembrolizumab in patients with triple negative breast cancer and adenocarcinoma of the lung.
M. Yule
,
K. Davidsen
,
+15 authors
J. Lorens
2018
Corpus ID: 80056333
TPS43Background: Activation of the receptor tyrosine kinase AXL has a profound suppressive effect on the innate immune system…
Expand
2018
2018
A randomized phase Ib/II study of the selective small molecule axl inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic…
O. Straume
,
C. Schuster
,
G. Gausdal
,
J. Lorens
,
B. Gjertsen
2018
Corpus ID: 81918991
9548Background: Upregulation of the receptor tyrosine kinase Axl has been linked with both a reduced response to PD-1 blockade…
Expand
2018
2018
Phase II open-label, multi-centre study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC.
J. Lorens
,
C. Arce-Lara
,
+14 authors
M. Chisamore
2018
Corpus ID: 80851225
3078Background: Bemcentinib (BGB324) is a first-in-class, oral, potent and highly selective inhibitor of the AXL tyrosine kinase…
Expand
2018
2018
A randomized phase Ib/II study of the selective small molecule Axl inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib (D/T) or pembrolizumab in patients with metastatic…
O. Straume
,
J. Lorens
,
G. Gausdal
,
B. Gjertsen
,
C. Schuster
Annals of Oncology
2018
Corpus ID: 226950648
Abstract Background Upregulation of the receptor tyrosine kinase Axl has been linked with both a reduced response to immune…
Expand
2017
2017
Abstract 626: BGB324, a selective small molecule inhibitor of receptor tyrosine kinase AXL, abrogates tumor intrinsic and microenvironmental immune suppression and enhances immune checkpoint…
K. Wnuk-Lipinska
,
K. Davidsen
,
+16 authors
J. Lorens
2017
Corpus ID: 80341852
The AXL receptor tyrosine kinase is associated with poor overall survival in a wide spectrum of cancers including lung and breast…
Expand
2016
2016
Single Cell Signaling Pharmacodynamics in a Phase 1b Trial of the Axl Inhibitor BGB324 in Acute Myeloid Leukemia
M. Hellesøy
,
Stein-Erik Gullaksen
,
+13 authors
B. Gjertsen
2016
Corpus ID: 79653380
Axl is a receptor tyrosine kinase that has been shown to have a strong oncogenic potential in many cancer types. Overexpression…
Expand
2015
2015
Axl inhibition: a potential road to a novel acute myeloid leukemia therapy?
M. Janning
,
I. Ben-Batalla
,
S. Loges
Expert Review of Hematology
2015
Corpus ID: 24669185
Novel treatment options in acute myeloid leukemia (AML) are urgently needed; treatment has not changed significantly over the…
Expand
2014
2014
BGB324 Represents an Axl and BCR-ABL1 Inhibitor with Activity in the T315I Mutant
R. Erdmann
,
H. Jørgensen
,
+28 authors
S. Loges
2014
Corpus ID: 77306338
BCR-ABL1 inhibitors have revolutionized the treatment of CML patients. However several drawbacks remain, including clinical…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE